Testing SNH-118110 for Advanced Cancers with RET Gene Changes
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called SNH-118110 in patients with advanced solid tumors that have a specific genetic change (RET alteration). The drug is designed to target and slow down cancer cells with this mutation. You may qualify if your cancer has this genetic change and standard treatments haven't worked or you couldn't tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can understand and sign the consent form
- You have advanced cancer (solid tumor) that has been confirmed by a biopsy or blood test
- Your cancer has a RET gene alteration (fusion or other activating change), confirmed by lab testing
- You have at least one tumor that can be measured on scans (RECIST criteria)
- Your overall health and activity level are good enough (ECOG 0–1: able to do light or no activities)
- You have a life expectancy of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
This study tests a new drug (HSK46256) for people with advanced solid tumors that have a specific DNA repair gene change (HRR mutation). It is a first-in-human trial to find the right dose and check safety, so it may be an option if other treatments have stopped working.
This early-phase study tests TSN222 in people with advanced, hard-to-treat solid tumors or lymphomas. It aims to see whether the drug can shrink tumors or improve outcomes, including in specific cancer types like head and neck cancer and melanoma.
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.